secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2022-06-29T23:59:59+00:00
Accession:  0000950170-22-012322
Event type: other
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Therapeutics 2022 Annual Meeting results: share count increase fails
-------------------------------------------------------------------------------

- Directors Roy Freeman and Paul Grint elected with ~11.4M and ~11.5M votes for; ~4.5M broker non-votes.
- Ratification of CohnReznick LLP as auditor approved: 16.4M for, 31.5K against, 56.6K abstain.
- Proposal to increase authorized shares from 100M to 200M failed: 15M for, 1.4M against, not meeting required percentage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000095017022012322/0000950170-22-012322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000095017022012322/ikt-20220624.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-012322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer